All In Biotech

Drug Trial Radar · NCT07483450

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis

A Multicenter, Open-label, Single-arm Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Chinese Patients With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis

Last checked: Nov 20, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Jul 4, 2025

Primary completion

Dec 31, 2027

Study completion Dec 31, 2028

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Mar 19, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to evaluate the efficacy of ocrelizumab in participants with relapsing multiple sclerosis (RMS) and to characterize the ocrelizumab pharmacodynamic (PD) profile in Chinese participants with primary progressive multiple sclerosis (PPMS).

Conditions

  • Relapsing Multiple Sclerosis
  • Primary Progressive Multiple Sclerosis

Interventions

  • OcrelizumabDrug

    Ocrelizumab will be administered as per the schedule specified in the respective arms.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. RMS Cohort: Annualized Protocol-defined Relapse RateTime frame: Up to approximately 1.6 years
  2. PPMS Cohort: B-cell Levels in BloodTime frame: Up to Week 48
  3. PPMS Cohort: Percentage of Participants Achieving Cluster of Differentiation 19 (CD19+) B-cell Levels of <10 Cells/Microliter (μL) at Week 48Time frame: At Week 48

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • Peking Union Medical College Hospital

    Beijing, China

  • Peking University First Hospital

    Beijing, China

  • Beijing Hospital of Ministry of Health

    Beijing, China

  • Xiangya Hospital Central South University

    Changsha, China

  • West China Hospital of Sichuan University

    Chengdu, China

  • The First Affiliated Hospital, Chongqing Medical University

    Chongqing, China

  • The First Affiliated Hospital of Sun Yat-sen University

    Guangzhou, China

  • The Third Affiliated Hospital of Sun Yat-Sen University

    Guangzhou, China

  • The First Affiliated Hospital of College of Medicine, Zhejiang University

    Hangzhou, China

  • Inner Mongolia Autonomous Region People's Hospital

    Hohhot, China

  • Lanzhou University Second Hospital

    Lanzhou, China

  • The First Hospital of China Medical University

    Shenyang, China

  • The Second Hospital of Hebei Medical University

    Shijiazhuang, China

  • 1st Affiliated Hospital of Shanxi Medical University

    Taiyuan, China

  • Xinjiang People Hospital

    Ürümqi, China

  • Tongji Hospital Tongji Medical College Huazhong University of Science and Technology

    Wuhan, China

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.